MedPath

Randomised, placebo controlled clinical trial to evaluate remifentanil as maternal sedation and fetal immobilisation during diagnostic prenatal MRI.

Phase 1
Conditions
Maternal sedation and fetal immobilization during MRI
Registration Number
EUCTR2009-011281-28-BE
Lead Sponsor
niversity Hospitals Leuven
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Female
Target Recruitment
50
Inclusion Criteria

Gestational age between 18 and 34 weeks
no contra indication for MRI
no allergy for remifentanil
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: 1. Evaluation of fetal immobilization during prenatal MRI<br>2. Evaluation of maternal sedation during prenatal MRI;Secondary Objective: ;Primary end point(s):
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath